Nicotinamide riboside is uniquely and orally bioavailable in mice and humans

Samuel A J Trammell, Mark S. Schmidt, Benjamin J. Weidemann, Philip Redpath, Frank Jaksch, Ryan W. Dellinger, Zhonggang Li, E. Dale Abel, Marie E. Migaud, Charles Brenner*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

276 Citations (Scopus)
326 Downloads (Pure)


Nicotinamide riboside (NR) is in wide use as an NAD + precursor vitamin. Here we determine the time and dose-dependent effects of NR on blood NAD + metabolism in humans. We report that human blood NAD + can rise as much as 2.7-fold with a single oral dose of NR in a pilot study of one individual, and that oral NR elevates mouse hepatic NAD + with distinct and superior pharmacokinetics to those of nicotinic acid and nicotinamide. We further show that single doses of 100, 300 and 1,000 mg of NR produce dose-dependent increases in the blood NAD + metabolome in the first clinical trial of NR pharmacokinetics in humans. We also report that nicotinic acid adenine dinucleotide (NAAD), which was not thought to be en route for the conversion of NR to NAD +, is formed from NR and discover that the rise in NAAD is a highly sensitive biomarker of effective NAD + repletion.

Original languageEnglish
Article number12948
Number of pages14
JournalNature Communications
Publication statusPublished - 10 Oct 2016
Externally publishedYes

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)


Dive into the research topics of 'Nicotinamide riboside is uniquely and orally bioavailable in mice and humans'. Together they form a unique fingerprint.

Cite this